Turn £10k Into £18.5k With GlaxoSmithKline plc

Even during a troubled decade, GlaxoSmithKline plc (LON: GSK) shares have performed reasonably.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

gskI took a look recently at AstraZeneca, and was impressed to see an overall trebling in value over the past 10 years if all dividends were reinvested.

The FTSE 100‘s other big pharmaceuticals company, GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) hasn’t been doing quite so well — for one thing, it hasn’t had its shares boosted by takeover fever.

A 20% gain?

If you’d invested £10,000 in GlaxoSmithKline shares 10 years ago, you’d have been paying around 1,191p apiece — and at that price you could have bagged 839 shares (ignoring dealing costs).

Now, the share price has only gained 21.5% over the period, and your ten grand would have grown to £12,149. While that might have matched cash in a savings account, we really expect better from investing in shares.

But that doesn’t include dividends, so what would those have added?

Rising dividends

GlaxoSmithKline has actually been paying pretty decent dividends, starting the period offering yields of around 3.5%. But that started ramping up in 2007 as the share price fell a little, reaching 5% by 2009 — and yields have remained close to that level since. 

One thing that does mean is that dividends alone would have easily been enough to beat cash sitting in the bank, without any share price gain!

Earnings per share (EPS) can be a little volatile, but even when EPS didn’t cover the dividend in 2010, Glaxo maintained the cash payment from its own resources — and EPS was back up to normal the next year.

Another five grand!

In total, GlaxoSmithKline would have paid you an extra £4,971 in dividends, taking your total to £17,120 — and a 71% rise is starting to look reasonable.

But what if, instead of taking and spending your cash handout each year, you had reinvested it in more Glaxo shares?

Before we look at that, let me mention a thing called pound cost averaging — it’s a fancy term that just means you’ll get more shares for the same money over a period when the price dips and recovers than if it had remained flat.

For Glaxo, what that means is that you’d have added just 24 new shares at the end of 2004 when the price was around 1,440p, but by 2007 when it had dropped to 1,210p you’d have scooped up 40 of them.

A decent result

Anyway, with dividends reinvested, you’d be ending the decade with £18,594 — and an 85.5% gain is really nothing to be sniffed at, especially for a share that has actually lagged the FTSE a little over the period (but with better than average dividend yields).

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

This 1 simple investing move accelerated Warren Buffett’s wealth creation

Warren Buffett has used this easy to understand investing technique for decades -- and it has made him billions. Our…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Down 6% in 2 weeks, the Lloyds share price is in reverse

After hitting a one-year high on 8 April, the Lloyds share price has suddenly reversed course. But as a long-term…

Read more »

Investing Articles

£3,000 in savings? Here’s how I’d use that to start earning a monthly passive income

Our writer digs into the details of how spending a few thousand pounds on dividend shares now could help him…

Read more »

Investing Articles

Here’s what dividend forecasts could do for the BP share price in the next three years

I can understand why the BP share price is low, as oil's increasingly seen as evil. But BP's a cash…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

This FTSE 100 Dividend Aristocrat is on sale now

Stephen Wright thinks Croda International’s impressive dividend record means it could be the best FTSE 100 stock to add to…

Read more »

Investing Articles

3 shares I’d buy for passive income if I was retiring early

Roland Head profiles three FTSE 350 dividend shares he’d like to buy for their passive income to support an early…

Read more »

Investing Articles

Here’s how many Aviva shares I’d need for £1,000 a year in passive income

Our writer has been buying shares of this FTSE 100 insurer, but how many would he need to aim for…

Read more »

Female Doctor In White Coat Having Meeting With Woman Patient In Office
Investing Articles

1 incredible growth stock I can’t find on the FTSE 100

The FTSE 100 offers us a lot of interesting investment opportunities, but there's not much in the way of traditional…

Read more »